Johnson & Johnson submits new drug application to FDA seeking expand pediatric indication for HIV-1 therapy Prezcobix
Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the FDA seeking to expand the indication of Prezcobix (darunavir/cobicistat) to include the treatment… read more.
